CPRX: Catalyst Pharmaceuticals EV/EBITDA Multiple
Catalyst Pharmaceuticals (CPRX) is striving to digitalize the accounting and logistics of rare medications. The company's dynamic EV/EBITDA ratio illustrates progress toward this goal, with the value holding at 10.08. However, high dependence on a single orphan drug and the necessity of patent protection constrain growth, despite the financial discipline of Patrick McAnany's team.
Analytical breakdowns for Catalyst Pharmaceuticals
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Debt to Equity Catalyst Pharmaceuticals|CPRX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Catalyst Pharmaceuticals, Inc.|CPRX - Company Cumulative Indebtedness|Debt to Book Value Catalyst Corp|CPRX - Company Long-Term Loans and Borrowings|Company Short-Term Debt Catalyst Pharmaceuticals|Quick Ratio catalystpharma.com
- business earnings and investment ratios data:
CPRX - Final Profit|Projected Future Earnings Catalyst Pharmaceuticals|CPRX - P/E Multiple|Future Price to Earnings Catalyst Pharmaceuticals|CPRX - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Corp|CPRX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Catalyst Pharmaceuticals|CPRX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth catalystpharma.com|CPRX - Net earnings per share growth this year|Earnings growth forecast for next year Catalyst Pharmaceuticals
General company analysis:Catalyst Pharmaceuticals Inc (CPRX)
This indicator assesses business value by accounting for net debt relative to earnings before interest, taxes, depreciation, and amortization, allowing for the determination of the asset's real price regardless of the financing structure. The Enterprise Value to EBITDA multiple trend for Catalyst Pharmaceuticals (CPRX) demonstrates the efficiency of capitalizing revenues from orphan drugs and the company's ability to accumulate resources for expansion into the rare neurological disease segment.
Key competitors
Biogen Corp - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio NBIX (Neurocrine Corp)|Regencell Bioscience - EV/EBITDA Multiple|AXSM - EV/EBITDA Multiple|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XENE (Xenon Pharmaceuticals Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio VKTX|Company Value to EBITDA Supernus Corp SUPN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Denali Therapeutics (DNLI)|Total Company Value to Operating Income Before Depreciation Ratio harmonybiosciences.com|Biohaven - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio AMLX (Amylyx Pharmaceuticals Inc)|TRVI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation PRAX (Praxis Corp)|Anavex Life Sciences (AVXL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CBLL (ceribell.com)|PRTA (Prothena Corporation plc) - EV/EBITDA Multiple|ALEC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANNX|EV/EBITDA Multiple omeros.com (OMER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Inc. NGNE|Business Value to Operating Income Before Depreciation ACIU|VYGR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Neumora (NMRA) - Enterprise Value to EBITDA Ratio|SCLX: EV/EBITDA Multiple|Tevogen Bio Inc. (TVGN) - EV/EBITDA Multiple|ACOG (Alpha Cognition Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cogrx.com (CGTX)|EV/EBITDA Multiple IKT|SAVA - Company Value to EBITDA|Assertio - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Coya Therapeutics Inc COYA|VTGN: Enterprise Value to EBITDA Ratio|Ovid Therapeutics Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|ABOS: EV/EBITDA Multiple|CRVO - Total Company Value to Operating Income Before Depreciation Ratio|ATHE (Alterity Therapeutics Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Clene Nanomedicine (CLNN)|EV/EBITDA Multiple PEPG|EV/EBITDA Multiple jupiterneurosciences.com (JUNS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|Annovis Bio Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Firefly Neuro AIFF|KLTO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NeuroSense Therapeutics Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|MetaVia, Inc. - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT (heliusmedical.com) - Business Value to Operating Income Before Depreciation|Passage Bio - Enterprise Value to EBITDA Ratio|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ATHA (Athira Pharma Inc) - Enterprise Value to Operating Income Before Depreciation|ADXN: EV/EBITDA Multiple|Company Value to EBITDA Alzamend Neuro (ALZN)|Enterprise Value to EBITDA Ratio CYCN|EV/EBITDA Multiple Protagenic|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BrainStorm Cell Therapeutics Inc. (BCLI) - Company Value to EBITDA|Cara Therapeutics, Inc. - EV/EBITDA Multiple|chromocell.com (CHRO) - Enterprise Value to EBITDA Ratio|ELYM: EV/EBITDA Multiple|Intra-Cellular Therapies, Inc. (ITCI) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio LBPH|MRNS (Marinus Pharma) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NKGN|EV/EBITDA Multiple neurobopharma.com (NRBO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|Synaptogenix Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVN: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Vigil Neuroscience|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CERE - Total Company Value to Operating Income Before Depreciation Ratio
